Fetal Gelişim ve Büyümede Apelinin Rolü

Abstract

Amaç: Umblikal kordon kanı serum apelin düzeyinin yenidoğanın doğum ağırlığı ve insülin direnci üzerinde etkisini belirlemektir. Gereç ve Yöntem: Benzer vücut kitle indeksine(VKİ) sahip, gestasyonel diyabeti bulunmayan annelerin gebelik haftasına göre büyük (GHB) ve gebelik haftasıyla uyumlu (GHU) yenidoğanlarından umblikal kordon kanı alındı. İşlem sonrası umblikal kordon kanı serumunda glukoz, insülin ve apelin düzeyi ölçüldü. Sonuçlarla HOMA-IR hesaplandı. Gruplar arasında demografik, klinik ve laboratuvar sonuçları karşılaştırıldı. Bulgular: Umblikal kordon kanı serum glukoz düzeyi açısından gruplar arasında fark saptanmadı. Ancak, umblikal kordon kanı serum insülin ve apelin düzeyi yüksek saptandı (sırasıyla, 11,7 ± 3,1 mIU/L, 6,8 ± 1,1 mIU/L, p:0,001, 10,4±4,2 ng/ml, 7,8±1,7 ng/ml, p:0,011). HOMA-IR değeri GHB grubunda daha yüksek hesaplandı (sırasıyla 3,0±1,2, 1,7±0,6, p:0,001). Umblikal kordon kanı serum apelin düzeyi ile doğum ağırlığı (r = 0.399, p = 0.006), umblikal kordon kanı serum insülin düzeyi (r:0,873, p:0,001) ve HOMA- IR değeri (r: 0,938, p:0,001) arasında istatistiksel açıdan anlamlı pozitif korelasyon saptanırken umblikal kordon kanı serum glukoz düzeyiyle herhangi bir korelasyon saptanmadı. Sonuç: GHB grubunda umblikal kordon kanı serum apelin düzeyinin daha yüksek olduğu tespit edildi. Bu düzeyin yenidoğanın doğum ağırlığı ve insülin direnciyle pozitif korele olduğu belirlendi.

Keywords

• apelin
• doğum ağırlığı
• İnsülin
• HOMA-IR

The Role OF APELIN in Fetal Growth and development

Abstract

Objective: To determine the effect of umbilical cord blood serum apelin level on newborn birth weight and insulin resistance. Materials and Methods: Umbilical cord blood was obtained from newborns who were large for gestational age (LGA) and appropriate for gestational age (AGA) of mothers who had similar body mass index (BMI) and did not have gestational diabetes. Glucose, insulin and apelin levels were measured in umbilical cord blood serum after the procedure. HOMA-IR was calculated with the results. Demographic, clinical and laboratory results were compared between the groups. Results: There was no difference between the groups in terms of umbilical cord blood serum glucose level. However, umbilical cord blood serum insulin and apelin levels were found to be high (11.7 ± 3.1 mIU/L, 6.8 ± 1.1 mIU/L, p:0.001, 10.4±4.2 ng/L, respectively). ml, 7.8±1.7 ng/ml, p:0.011). The HOMA-IR value was higher in the LGA group (3.0±1.2, 1.7±0.6, p:0.001, respectively). While a statistically significant positive correlation was found between umbilical cord blood serum apelin level and birth weight(r = 0.399, p = 0.006) , umbilical cord blood serum insulin level (r:0,873, p:0,001) and HOMA-IR value (r: 0,938, p:0,001) , it was not determined by umbilical cord blood serum glucose level. Conclusion: Umbilical cord blood serum apelin level was found to be high in the LGA group. This level was found to be positively correlated with newborn birth weight and insulin resistance.

Keywords

• Apelin
• birth weight
• Insulın
• HOMA-IR

References

1. 1. Hadfield RM, Lain SJ, Simpson JM, Ford JB, Raynes‐Greenow CH, Morris JM, et al. Are babies getting bigger? An analysis of birthweight trends in New South Wales, 1990–2005. Medical Journal of Australia 2009;190:312-5.
2. 2. Kramer MS, Morin I, Yang H, Platt RW, Usher R, McNamara H, et al. Why are babies getting bigger? Temporal trends in fetal growth and its determinants. The Journal of pediatrics 2002;141:538-42.
3. 3. Lu Y, Zhang J, Lu X, Xi W, Li Z. Secular trends of macrosomia in southeast China, 1994-2005. BMC public health 2011;11:818.
4. 4. Khambalia AZ, Algert CS, Bowen JR, Collie RJ, Roberts CL. Long‐term outcomes for large for gestational age infants born at term. Journal of paediatrics and child health 2017;53:876-81.
5. 5. Weıssmann‐Brenner A, Simchen MJ, Zilberberg E, Kalter A, Weisz B, Achiron R, et al. Maternal and neonatal outcomes of large for gestational age pregnancies. Acta obstetricia et gynecologica Scandinavica 2012;91:844-9.
6. 6. Smith NC, Rowan P, Benson LJ, Ezaki M, Carter PR. Neonatal brachial plexus palsy: outcome of absent biceps function at three months of age. JBJS 2004;86:2163-70.
7. 7. Algert C, McElduff A, Morris J, Roberts C. Perinatal risk factors for early onset of type 1 diabetes in a 2000–2005 birth cohort. Diabetic medicine 2009;26:1193-7.
8. 8. Lunde A, Melve KK, Gjessing HK, Skjærven R, Irgens LM. Genetic and environmental influences on birth weight, birth length, head circumference, and gestational age by use of population-based parent-offspring data. American journal of epidemiology 2007;165:734-41.

9. 9. Clausson B, Lichtenstein P, Cnattingius S. Genetic influence on birthweight and gestational length determined by studies in offspring of twins. BJOG: An International Journal of Obstetrics & Gynaecology 2000;107:375-81.
10. 10. Moyer-Mileur LJ, Slater H, Thomson JA, Mihalopoulos N, Byrne J, Varner MW. Newborn adiposity measured by plethysmography is not predicted by late gestation two-dimensional ultrasound measures of fetal growth. J Nutr. 2009;139:1772–1778.
11. 11. Dessi A, Pravettoni C, Cesare Marincola F, Schirru A, Fanos V. The biomarkers of fetal growth in intrauterine growth retardation and large for gestational age cases: from adipocytokines to a metabolomic all-in-one tool. Expert review of proteomics 2015;12:309-16.
12. 12. Kiess W, Petzold S, Topfer M, Garten A, Bluher S, Kapellen T, et al. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab 2008;22:135-53.
13. 13.Waller JD, McNeill EH, Zhong F, Vervaecke LS, Goldfarb AH. Plasma Apelin unchanged with acute exercise insulin sensitization. J Sports Sci Med. 2019;18:537–543
14. 14. Eberlé D, Marousez L, Hanssens S, et al. Elabela and Apelin actions in healthy and pathological pregnancies. Cytokine Growth Factor Rev. 2019;46:45-53. doi:10.1016/j.cytogfr.2019.03.003
15. 15. Kidoya H, Ueno M, Yamada Y, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J. 2008;27(3):522-534. doi:10.1038/sj.emboj.7601982
16. 16. Furuya M, Okuda M, Usui H, et al. Expression of angiotensin II receptor-like 1 in the placentas of pregnancy-induced hypertension. Int J Gynecol Pathol. 2012;31(3):227-235. doi:10.1097/PGP.0b013e31823b6e71
17. 17. Liao YM, Qiao FY. [Expression of Apelin in placentas of patients with hypertensive disorders complicating pregnancy]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):382-5. Chinese. PMID: 17697598.
18. 18. Inuzuka H, Nishizawa H, Inagaki A, et al. Decreased expression of apelin in placentas from severe pre-eclampsia patients. Hypertens Pregnancy. 2013;32(4):410-421. doi:10.3109/10641955.2013.813535
19. 19. Kucur M, Tuten A, Oncul M, et al. Maternal serum apelin and YKL-40 levels in early and late-onset pre-eclampsia. Hypertens Pregnancy. 2014;33(4):467-475. doi:10.3109/10641955.2014.944709
20. 20. Simsek Y, Celik O, Yilmaz E, et al. Serum levels of apelin, salusin-alpha and salusin-beta in normal pregnancy and preeclampsia. J Matern Fetal Neonatal Med. 2012;25(9):1705-1708. doi:10.3109/14767058.2011.660221
21. 21. Bertrand C, Valet P, Castan-Laurell I. Apelin and energy metabolism. Front Physiol. 2015;6:115. Published 2015 Apr 10. doi:10.3389/fphys.2015.00115 22. Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008;8(5):437-445. doi:10.1016/j.cmet.2008.10.003
22. 23. Akcılar R, Turgut S, Caner V, et al. The effects of apelin treatment on a rat model of type 2 diabetes. Adv Med Sci. 2015;60(1):94-100. doi:10.1016/j.advms.2014.11.001
23. 24. Chaves-Almagro C, Castan-Laurell I, Dray C, Knauf C, Valet P, Masri B. Apelin receptors: From signaling to antidiabetic strategy. Eur J Pharmacol. 2015;763(Pt B):149-159. doi:10.1016/j.ejphar.2015.05.017
24. 25. Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer. Front Physiol. 2018;9:557. Published 2018 May 23. doi:10.3389/fphys.2018.00557
25. 26. Noori-Zadeh A, Bakhtiyari S, Khanjari S, Haghani K, Darabi S. Elevated blood apelin levels in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;148:43-53. doi:10.1016/j.diabres.2018.12.012
26. 27. Krist J, Wieder K, Klöting N, et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts. 2013;6(1):57-69. doi:10.1159/000348667
27. 28. Telejko B, Kuzmicki M, Wawrusiewicz-Kurylonek N, et al. Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus. Diabetes Res Clin Pract. 2010;87(2):176-183. doi:10.1016/j.diabres.2009.10.018
28. 29. Oncul M, Tuten A, Erman H, Gelisgen R, Benian A, Uzun H. Maternal and cord blood apelin, resistin and visfatin levels in gestational diabetes mellitus. Minerva Med. 2013;104(5):527-535.
29. 30. Cundubey C, Tayyar A, Maternal and fetal apelin levels in gestational diabetes mellitus. Bozok Med J. 2017;7(3): 58–66
30. 31. Bellos, I., Fitrou, G., Pergialiotis, V., Perrea, D. N., & Daskalakis, G. (2019). Serum levels of adipokines in gestational diabetes: a systematic review. Journal of endocrinological investigation, 42(6), 621–631. https://doi.org/10.1007/s40618-018-0973-2
31. 32. Wang G, Anini Y, Wei W, et al. Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology. 2004;145(3):1342-1348. doi:10.1210/en.2003-1116
32. 33. Mayeur S, Wattez JS, Lukaszewski MA, et al. Apelin Controls Fetal and Neonatal Glucose Homeostasis and Is Altered by Maternal Undernutrition. Diabetes. 2016;65(3):554-560. doi:10.2337/db15-0228
33. 34. Cekmez F, Canpolat FE, Pirgon O, Çetinkaya M, Aydinoz S, Suleymanoglu S, et al. Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance. Cytokine 2011;56:387-91.